

Extended Levodopa Release from a Subcutaneously Implanted Polymer Matrix in Rats

B. A. Sabel, PhD,* P. Dominiak, MD,† W. Häuser, MA,† M. J. Doring, MD, FRACP,‡§ and A. Freese, MD, PhD#||

It is well recognized that plasma fluctuations resulting from oral levodopa therapy may cause an unstable clinical response in parkinsonian patients. We have therefore developed a slow-release polymer matrix system that can deliver levodopa continuously for extended periods of time (at least 225 days) after subcutaneous implantation in rats. Advantages of this approach include (1) the elimination of levodopa plasma fluctuations and (2) the possibility of reducing the required dose due to constant plasma levels and because the gastrointestinal tract is circumvented. The peripheral implantation of polymer systems containing levodopa, dopamine receptor agonists, or other anti-Parkinson agents may constitute a novel technology of drug delivery to improve the care of patients with Parkinson's disease.

Sabel BA, Dominiak P, Häuser W, Doring MJ, Freese A. Extended levodopa release from a subcutaneously implanted polymer matrix in rats. *Ann Neurol* 1990;28:714-717

The majority of parkinsonian patients show a reasonably stable clinical response to oral levodopa (L-Dopa)

From the Institutes of *Medical Psychology and †Physiology, University of Munich Medical School, Munich, FRG, the ‡Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, the §Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, and the ||Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA.

Received Jan 22, 1990, and in revised form May 29. Accepted for publication Jun 2, 1990.

Address correspondence to Dr Sabel, Institute of Medical Psychology, University of Munich Medical School, Goethestr. 31, 8000 Munich 2, FRG.

therapy, despite plasma L-Dopa fluctuations [1, 2]. After several years of therapy, the patient responses begin to fluctuate, and L-Dopa treatment is less effective [3]. In many patients, these clinical fluctuations are parallel to fluctuations in plasma L-Dopa levels [3, 4], and it is therefore desirable to obtain constant plasma levels of L-Dopa through improved modes of drug delivery. A variety of methods have been developed to date for the improved delivery of L-Dopa or dopamine receptor agonists. They include intraventricular infusion [4, 5], implantable or external reservoir pump systems [6], and oral slow release preparations such as Sinemet CR3 - CR5 [7, 8] and Madopar HBS [9] as well as others [10-13]. Although each approach appears to provide some benefits, none of them combines convincing features of practicability with unequivocal efficacy. We have therefore developed a peripherally implantable controlled-release polymer system, and we now document continuous L-Dopa delivery in rats for more than 200 days after subcutaneous implantation.


Methods

Ethylene vinyl acetate copolymer (EVA) containing 70% (wt/wt) L-Dopa (Sigma Chemical, St. Louis, MO) was prepared by using a method similar to one described previously [14], resulting in rectangular samples (15 × 30 × 2 mm, total weight 1.3 g). Figure 1A displays a schematic to illustrate the polymer composition and mechanism of drug release. Figure 1B shows a cross-section through one such polymer matrix containing L-Dopa crystals by using scanning electron microscopy (SEM, magnification × 300). Based on in vitro observations (see also [14]), we expected a non-coated polymer matrix with 70% loading to provide a maximal release rate. Therefore, in vitro release of L-Dopa from such samples was monitored by using spectrophotometric analysis in conjunction with high performance liquid chromatography (HPLC) (see legend of Fig 2A).

For the in vivo experiment, three Male Sprague-Dawley rats (290-360 gm) were anesthetized with ether, and an L-Dopa-containing implant (70% loading) was inserted subcutaneously through a small incision into each rat. A control rat received an unloaded implant (without L-Dopa). On the day after implantation and at various times thereafter, 700 to 800- μ l blood samples were drawn from the tail vein (ether anesthesia), collected in vials containing 20 μ l glutathione-ethylenediaminetetraacetic acid solution (pH 6-7), vortexed, and centrifuged at 4°C for 10 minutes at 4,000 rpm. Plasma was then stored at -70°C until samples were assayed for catecholamines by using HPLC according to a previously published method [15] (see also legend of Fig 2).

Results

SEM analysis at × 300 (see Fig 1B) shows L-Dopa crystals embedded in the polymer matrix. The matrix contains small channels and pores through which L-Dopa dissolves into the aqueous environment. Spec-



A



B

Fig 1. (A) Shows the mechanism of drug release from slow-release matrix-type polymer. A slow-release polymer consists of a continuous phase of polymer carrier (gray area) with a dispersed phase of drug powder particles (black circles). The polymer displayed in this graph has an impermeable barrier (solid black line) around all but one side through which the drug can diffuse out. When the polymer is exposed to an aqueous environment (e.g., saline), the outermost drug particle layer dissolves and the drug enters the environment (arrows) by passive dissolution through pores and channels in the polymer. As time proceeds, the medium dissolves further layers of drug particles, until the polymer is empty, without destroying the polymer itself. (B) Scanning electronmicrograph of levodopa (L-Dopa) containing polymer matrix at a magnification of × 300. L-Dopa crystals (arrows) can clearly be distinguished from the polymer matrix (P) before release commences. Pores and channels, through which the drug dissolves into the aqueous environment, can also be seen.

trophotometric evaluation of in vitro release revealed continuous L-Dopa release for at least 225 days. After subcutaneous implantation, the mean plasma L-Dopa level was relatively high in the initial period of release, ranging from 220 to 700 ng/ml (mean of 480 ng/ml, see Fig 2B). After about 50 days, this level decreased by approximately 90%, and release approached linearity thereafter. In 1 rat, zero-order kinetics were




Fig 2. (A) *In vitro* release of levodopa (L-Dopa) (mg) from quadruplicates of polymer matrices with 70% loading (mean \pm SE). To measure release, polymer matrices and controls were individually immersed in glass scintillation vials containing 20 ml 150 mM sodium chloride, 0.2% ethylenediaminetetraacetic acid (EDTA) solution (as antioxidant) and then incubated at 37°C on a light-protected rotating platform. L-Dopa release was determined by spectrophotometric analysis (wave length of 280 nm), replacing the bathing solution each time measurements were taken to avert saturation. Quantification of release was performed by comparison of spectrophotometric values of samples to known standards. (B) Mean \pm SE of L-Dopa levels (ng/ml) in plasma of rats either implanted with L-Dopa containing polymer matrices ($n = 3$) or with nonloaded blank polymers (control, $n = 1$). The high performance liquid chromatography (HPLC) assay of the plasma catecholamine content was initiated by adding 10 μ l 5 M HClO₄ for 2 minutes to precipitate proteins in the previously collected samples. After additional centrifuging, the supernatant was placed into Eppendorf tubes containing 20 ng activated aluminum oxide (Al₂O₃) and 100 μ l reduced glutathione (GSH) EDTA. By adding Tris-buffer (pH 8.7), plasma catecholamines were adsorbed by Al₂O₃. The saturated Al₂O₃ was then washed three times (1 ml Tris-buffer, 1 ml GSH-EDTA solution, 98 ml HPLC-water) and centrifuged, and the supernatant was discarded. Desorption was performed by adding 100 μ l 0.2 M HClO₄, and aliquots were injected into an HPLC system (Waters) by using a Macherey & Nagel column (Nucleosil 5C18, 20 cm) and electrochemical detection (Waters M 460). The mobile phase was citrate buffer with 1% methanol and 60 mg/l octanesulfonic acid to yield a final pH of 3.2 (flow rate 0.8 ml/min, 2,800 psi). The content of L-Dopa was calculated by comparing the samples to an internal standard of the synthetic catecholamine dihydroxybenzylamine and to analytical standards (20 ng/ml).

achieved, with a release of at least 8 ng L-Dopa/ml from Day 84 through at least Day 225, at which time the experiment was terminated. The control rat had a mean plasma L-Dopa level of 1.66 ± 0.16 ng/ml. Thus, the polymer implants resulted in continuous L-Dopa release to obtain stably elevated plasma L-Dopa levels *in vivo* for more than one-half year, which were fourfold to eightfold higher than control levels. The release kinetics *in vivo* (see Fig 2B) are very similar to those observed *in vitro* (see Fig 2A).

Discussion

Numerous investigators have now shown that continuous delivery of L-Dopa constitutes the best mode of treatment for parkinsonian patients, and a number of methods have been developed to obtain improved drug delivery. Using a controlled release polymer matrix system, we have now obtained L-Dopa release for an extended period of time (more than 225 days). After subcutaneous implantation in rats, this approach results in stable L-Dopa levels of at least fourfold to eightfold above normal. Using the same polymer matrix system, we have also previously reported that extended delivery of dopamine can be obtained both *in vitro* and in the brain [14, 16].

The following are several reasons suggesting that our polymer system is potentially valuable for the controlled delivery of anti-Parkinson agents: (1) it appears that both the rate of release and the service lifetime of the peripheral implants are adequate, (2) the polymer matrices are biocompatible, (3) sustained release eliminates the drug plasma fluctuations, and (4) circumvention of the gastrointestinal tract may permit a significant reduction in dose. This is supported by the observation that when infused through duodenal tubes in human parkinsonian patients, the 24-hour dose requirement for L-Dopa is decreased significantly [13].

Yet, other advantages of our approach are that (5) drugs (such as L-Dopa) embedded in polymer matrices have long-term biological activity exceeding that of drugs that are suspended in solution as, for example, with reservoir pumps, (6) the polymer can easily be replaced or removed if medical or psychiatric problems arise, and (7) the polymer implants can eliminate the compliance problems seen in some patients.

It can be argued that polymer implants do not provide sufficient flexibility to adjust the dose for an individual patient. An appropriate daily dose of L-Dopa for a particular patient could first be determined, however, by using intravenous duodenal infusion, followed by selection of an appropriate polymer sample and subcutaneous implantation into patients in an ambulatory setting.

Implants are expected to benefit primarily patients with response fluctuations, that is, patients in the later

stages of the disease, but polymer implants, due to their virtue of keeping the dose constant and relatively low, may also be able to retard or preclude the appearance of the "on-off" and "end-of-dose" responses when implanted early in the disease. Thus, peripheral implantation of polymer matrices containing L-Dopa or dopamine receptor agonists might comprise a useful method of drug delivery to improve the treatment of Parkinson's disease.

References

1. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. *Ann Neurol* 1987;22:475-479
2. Hardie RJ, Lees AJ, Stern GM. Pharmacokinetics of levodopa and motor fluctuations. *Advances in Neurology*, vol 45, Parkinson's Disease. New York: Raven Press, 1986:487-492
3. Shoulson I, Glaubiger GA, Chase TN. On-off response. *Neurol* 1975;25:1144-1148
4. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. *Brain* 1984;107:487-506
5. Quinn NP, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. *Lancet* 1982;2:412-415
6. Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. *Lancet* 1986;1:467-470
7. Cedarbaum JM, Breck L, Kutt H, McDowell FH. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease. *Neurol* 1987;37:233-241
8. Nutt JG, Woodward WR, Carter JH. Clinical and biochemical studies with controlled-release levodopa/carbidopa. *Neurol* 1986;36:1206-1211
9. Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. *Eur Neurol* 1987;27:21-27
10. Curzon G, Friedel J, Grier L, et al. Sustained-release levodopa in Parkinsonism. *Lancet* 1973:781
11. Lataste X, Drewe J, Abisch E, et al. Parlodel (bromocriptine mesylate) sustained-release preparation for Parkinsonism. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. *Recent Developments in Parkinson's Disease*, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:221-227
12. Saarinne A, Myllylä VV, Tokola O, Hokkanen E. Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor. *Acta Neurol Scand* 1978;58:340-349
13. Sage JI, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in Parkinsonism. *Ann Neurol* 1988;24:87-89
14. Freese A, Sabel BA, Saltzman WM, et al. Controlled release of dopamine from a polymeric brain implant: in vitro characterization. *Exp Neurol* 1989;103:234-238
15. Hjendahl P. Inter-laboratory comparison of plasma catecholamine determinations using several different assays. *Acta Physiol Scand* 1984;527(suppl):43-54
16. During MJ, Freese A, Sabel BA, et al. Controlled release of dopamine from a polymeric brain implant: in vivo characterization. *Ann Neurol* 1989;25:351-356